146
Participants
Start Date
September 28, 2009
Primary Completion Date
December 29, 2010
Study Completion Date
December 29, 2010
SB656933
20 mg
SB656933
50mg
Placebo
placebo
GSK Investigational Site, Albany
GSK Investigational Site, Berlin
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Philadelphia
GSK Investigational Site, Hamburg
GSK Investigational Site, Atlanta
GSK Investigational Site, Haifa
GSK Investigational Site, Pessac
GSK Investigational Site, Montpellier
GSK Investigational Site, Birmingham
GSK Investigational Site, Cleveland
GSK Investigational Site, Akron
GSK Investigational Site, Bochum
GSK Investigational Site, Essen
GSK Investigational Site, Cincinnati
GSK Investigational Site, Petah Tikva
GSK Investigational Site, Reims
GSK Investigational Site, Milwaukee
GSK Investigational Site, Lille
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Chicago
GSK Investigational Site, Tübingen
GSK Investigational Site, Paris
GSK Investigational Site, Houston
GSK Investigational Site, Denver
GSK Investigational Site, Tucson
GSK Investigational Site, Jerusalem
GSK Investigational Site, Palo Alto
GSK Investigational Site, Worcester
GSK Investigational Site, Colchester
GSK Investigational Site, Madison
GSK Investigational Site, Toronto
GSK Investigational Site, Montreal
Lead Sponsor
GlaxoSmithKline
INDUSTRY